Shares of ConvaTec Group PLC (LON:CTEC – Get Free Report) have been assigned an average rating of “Buy” from the six research firms that are covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is GBX 320.33.
CTEC has been the topic of a number of analyst reports. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of ConvaTec Group in a report on Wednesday, July 30th. Berenberg Bank dropped their price objective on ConvaTec Group from GBX 335 to GBX 330 and set a “buy” rating on the stock in a report on Tuesday, August 19th. Royal Bank Of Canada upgraded ConvaTec Group to an “outperform” rating and cut their price objective for the stock from GBX 320 to GBX 315 in a research report on Thursday, August 21st. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 315 target price on shares of ConvaTec Group in a research report on Wednesday, July 30th. Finally, UBS Group reiterated a “buy” rating and issued a GBX 375 price target on shares of ConvaTec Group in a report on Friday.
Read Our Latest Stock Report on ConvaTec Group
Insider Activity
ConvaTec Group Stock Performance
Shares of LON CTEC traded up GBX 2.20 during trading hours on Friday, reaching GBX 235.80. The stock had a trading volume of 4,567,398 shares, compared to its average volume of 14,153,500. The firm has a 50-day moving average of GBX 238.26 and a 200-day moving average of GBX 252.97. The firm has a market cap of £4.68 billion, a price-to-earnings ratio of 22.25, a PEG ratio of 0.93 and a beta of 0.64. ConvaTec Group has a fifty-two week low of GBX 213.40 and a fifty-two week high of GBX 311.20. The company has a current ratio of 2.26, a quick ratio of 0.96 and a debt-to-equity ratio of 85.32.
About ConvaTec Group
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns.
Further Reading
- Five stocks we like better than ConvaTec Group
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Cameco Stock Falls After Earnings, Why the Dip May Be a Gift
- How to Short a Stock in 5 Easy Steps
- Amgen Stock: New All-Time Highs Ahead After Earnings Beat
- How to Read Stock Charts for Beginners
- Netflix Stock Split Explained: What It Means for Investors
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.
